1,1-dimethylethyl-2-(5-phenyl-1,3,4-oxadiazol-2-yl)-1-pyrrolidinecarboxylate | 341543-69-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1,1-dimethylethyl-2-(5-phenyl-1,3,4-oxadiazol-2-yl)-1-pyrrolidinecarboxylate
• 英文别名: Tert-butyl 2-(5-phenyl-1,3,4-oxadiazol-2-yl)pyrrolidine-1-carboxylate
• CAS: 341543-69-9
• 化学式: C₁₇H₂₁N₃O₃
• 分子量: 315.372
• InChiKey: BJGCVXTYUFBDFS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  68.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1(S)-2-(N'-benzoyl-hydrazinocarbonyl)-pyrrolidine-1-carboxylic acid tert-butyl ester 在 N,N-二异丙基乙胺 、 对甲苯磺酰氯 作用下， 以 乙腈 为溶剂， 生成 1,1-dimethylethyl-2-(5-phenyl-1,3,4-oxadiazol-2-yl)-1-pyrrolidinecarboxylate
  参考文献：
  名称：

  Mild and convenient one-pot synthesis of 1,3,4-oxadiazoles

  摘要：

  A mild, general, convenient, and efficient one-pot synthesis of 2-phenyl-5-substituted-1,3,4-oxadiazoles is described. Both (hetero)aryl and alkyl carboxylic acids were efficiently condensed with benzohydrazide in the presence of TBTU to give diacylhydrazine intermediates. The latter underwent a smooth TsCl-mediated cyclodehydration reaction to afford 2-phenyl-5-substituted-1,3,4-oxadiazoles in good to very good yields. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2010.06.139

文献信息

• Dpp-IV Inhibitors
  申请人：Edwards John Paul

  公开号：US20080015146A1

  公开（公告）日：2008-01-17

  The invention relates to compounds of formula (I) wherein Z, R 1-9 , n, A, X and R b have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.

  本发明涉及公式(I)的化合物，其中Z、R1-9、n、A、X和Rb的含义如所述描述和权利要求中所述。所述化合物可用作DPP-IV抑制剂。本发明还涉及制备这些化合物的方法，以及作为药物的生产和使用。
• OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20150252032A1

  公开（公告）日：2015-09-10

  The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives of formula (I) wherein R, and the rings A 1 A 2 and A 3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.

  本发明涉及公式（I）的[ortho bi-（hetero-）aryl]-[2-（meta bi-（hetero-）aryl）-pyrrolidin-1-yl]-methanone衍生物，其中R和环A1A2和A3如描述中所述，以及其药学上可接受的盐、其制备方法、含有一个或多个公式（I）化合物的制药组合物以及它们作为药物的用途，特别是作为促进睡眠激素受体拮抗剂的用途。
• DPP-IV INHIBITORS
  申请人：Santhera Pharmaceuticals (Schweiz) AG

  公开号：EP1786806A1

  公开（公告）日：2007-05-23
• OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES
  申请人：Idorsia Pharmaceuticals Ltd

  公开号：EP2906553B1

  公开（公告）日：2019-06-26
• US9493446B2
  申请人：——

  公开号：US9493446B2

  公开（公告）日：2016-11-15